BIO Issues Statement on Hepatitis C medicines report.
Share:
Press Release Summary:
In his statement regarding report released by Senators Grassley and Wyden, BIO Senior VP of Communications Kenneth Lisaius stated that BIO is reviewing said report in full and generally does not comment on product pricing by member companies. Lisaius added, however, that "balanced debate about the cost of groundbreaking cures" cannot narrow their focus on price but also acknowledge value provided to patients as well as overall healthcare system.
Original Press Release:
BIO Statement on Hepatitis C Medicines Report from Senators Grassley and Wyden
WASHINGTON--The following statement regarding the report released today by Senators Grassley and Wyden may be attributed to BIO Senior Vice President of Communications Kenneth Lisaius:
“We currently are reviewing the full report and generally do not comment on product pricing by member companies. That said, we believe that any balanced debate about the cost of groundbreaking cures like these new Hepatitis C medicines cannot focus narrowly on their price, but also must acknowledge the tremendous value they provide to patients and the overall healthcare system. Next-generation Hepatitis C drugs are making a real difference in patients’ lives, with cure rates of up to 99 percent for this seriously debilitating disease. Curing Hepatitis C also averts the need for more costly treatments down the road, such as liver transplants which can often cost $500,000 for a single patient. A 2013 paper in Hepatology estimated average lifetime treatment costs (including medical inflation) for uncured Hepatitis C at over $200,000 per patient. Many independent evaluations of the value of these drugs, including a recently released JAMA study which found that Harvoni was cost-effective across all ranges of disease severity, have concluded that these medicines offer a good value for the cost. BIO welcomes a discussion about the true value of biopharmaceutical innovation.”
About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.
Upcoming BIO Events
BIO International Convention
June 6-9, 2016
San Francisco, Calif.
BIO CEO & Investor Conference
February 8-9, 2016
New York, New York
13th Annual BIO Asia International Conference
March 15-16, 2016
Tokyo, Japan
BIO-Europe Spring
April 4-6, 2016
Stockholm, Sweden
Contacts
Biotechnology Industry Organization
Daniel Seaton, 202-470-5207
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech
